23

General Information


DRACP ID  DRACP00166

Peptide Name   23

Sequence  YGGFMX

Sequence Length  6

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HEp-2 Human papillomavirus-related endocervical adenocarcinoma Carcinoma 3.9% inhibition at 10-5 M, 45.0% inhibition at 10-3 M MTT assay 72 h 1
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma 9.3% inhibition at 10-3 M MTT assay 72 h 1
HBL Melanoma Carcinoma 4.1% inhibition at 10-6 M, 70.7% inhibition at 10-5 M, 34.2% inhibition at 10-3 M MTT assay 72 h 1
HT-29 Colon adenocarcinoma Carcinoma 9.2% inhibition at 10-3 M MTT assay 72 h 1
CaCo-2 Colon adenocarcinoma Carcinoma 11.8% inhibition at 10-5 M, 47.0% inhibition at 10-3 M MTT assay 72 h 1
MCF-7 Invasive breast carcinoma of no special type Carcinoma 2.2% inhibition at 10-6 M, 7.1% inhibition at 10-5 M, 6.9% inhibition at 10-4 M, 25.9% inhibition at 10-3 M MTT assay 72 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  lead to apoptosis

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  X=Cαα -dialkylated glycine (Aaa1 )

Chiral  L



Physicochemical Information


Formula  C27H33N5O6S

Absent amino acids  ACDEHIKLNPQRSTVW

Common amino acids  G

Mass  75501

Pl  6.09

Basic residues  0

Acidic residues  0

Hydrophobic residues  1

Net charge  0

Boman Index  707

Hydrophobicity  43.33

Aliphatic Index  0

Half Life 
  /

Extinction Coefficient cystines  1490

Absorbance 280nm  298

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 16722632

Title  Tumor-cell-targeted methionine-enkephalin analogues containing unnatural amino acids: design, synthesis, and in vitro antitumor activity

Doi 10.1021/jm051026

Year  +2006

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.